Price
No data yet.
Social Signal Score
Revenue
$18.0K-98.69%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Keith Murphy
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 15
- Beta
- 1.49
- Country
- US
- Piotroski score
- 1 / 9 (Weak)
- Altman Z-score
- -140.12
Financials
Revenue
$18.0K-98.7%Net Income
$-1.34MEBITDA
$-1.29MFree Cash Flow
$-3.24MEPS (diluted)
$-0.25Shares Outstanding (diluted)
5.24M+1249.4%Operating Expenses
$2.78MCash & Debt
$1.67MRevenue by Segment (annual)
$131.0KQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2026 | $131.0K | $-13.84M | $-5.35 |
| 2025 | $144.0K | $-2.49M | $-1.70 |
| 2024 | $109.0K | $-14.67M | $-19.25 |
| 2023 | $370.0K | $-17.26M | $-23.77 |
| 2022 | $1.50M | $-11.45M | $-15.78 |
| 2021 | $0.00 | $-16.83M | $-29.25 |
| 2020 | $2.20M | $-18.71M | $-34.66 |
| 2019 | $3.09M | $-26.64M | $-55.40 |
| 2018 | $4.60M | $-34.80M | $-77.89 |
| 2017 | $4.23M | $-38.45M | $-94.38 |
| 2016 | $1.48M | $-38.58M | $-102.80 |
| 2015 | $571.0K | $-30.08M | $-90.64 |
| 2014 | $379.0K | $-25.85M | $-84.82 |
| 2013 | $1.20M | $-43.55M | $-242.24 |
Valuation
VIVShas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
60-40.00%Social Signal Score
Mentions (3)
- Newsglobenewswire.com·5h ago·Negative
VivoSim Labs Celebrates Updated FDA Regulations Allowing Greater use of Non-Animal Testing Methods As the FDA opens the door to non-animal safety testing, VivoSim's human-relevant models are already helping lower drug costs As the FDA opens the door to non-animal safety testing, VivoSim's human-relevant models are already helping lower drug costs
View source ↗ - Newsglobenewswire.com·21d ago·Negative
VivoSim Labs Unveils New NAMkind™ Drug Toxicity Data at EUROTOX 2026, Demonstrating Predictive Superiority in Liver and Gastrointestinal Safety Across Small Molecules and ADCs New data presented in Vienna highlights long-term repeat-dose modeling, mechanistic GI barrier profiling, and deconvolution of payload- and linker-dependent toxicities for complex modalities New data presented in Vienna highlights long-term repeat-dose modeling, mechanistic GI barrier profiling, and deconvolution of payloa
View source ↗ - Newsglobenewswire.com·36d ago·Neutral
VivoSim Labs to Add Rat Liver Model to NAMkind Platform New cross-species capability is designed to help pharma distinguish rat-specific liver toxicity from risks that may translate to humans New cross-species capability is designed to help pharma distinguish rat-specific liver toxicity from risks that may translate to humans
View source ↗
Earnings
Thu, Nov 5(in 4 weeks)
Typical surprise +57.0% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Jul 14$-2.21 vs $-2.04miss
- Wed, Feb 11$-1.03 vs $-2.40beat
- Thu, Nov 6$-0.98 vs $-2.28beat
- Fri, May 30$-3.48 vs $-2.28miss
- Wed, Feb 19$-0.19 vs $-2.52beat
Estimates and results for VIVS via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by VIVS officers and directors.
- Bought
- $3k
- Sold
- $7k
1 trade
1 trade
- Lialin Tony Sergebought
- Gobel Davidsold
9 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in VIVS.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.